SJ-172550 NEW
| Price | $59 | $97 | $195 |
| Package | 5mg | 10mg | 25mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-11-09 |
Product Details
| Product Name: SJ-172550 | CAS No.: 431979-47-4 |
| Purity: 99.87% | Supply Ability: 10g |
| Release date: 2025/11/09 |
Product Introduction
Bioactivity
| Name | SJ-172550 |
| Description | SJ-172550 is a small molecule inhibitor of MDMX (EC50: 5 μM). |
| In vitro | SJ-172550 interacts with the p53-binding pocket of MDMX, effectively displacing p53 and reversibly binding to MDMX, resulting in the death of retinoblastoma cells with amplified MDMX expression. This compound establishes a covalent, yet reversible, complex with MDMX, which prohibits MDMX from binding to p53. The efficacy of SJ-172550 is enhanced when used in conjunction with the MDM2 inhibitor, nutlin-3a. The stability of the SJ-172550/MDMX complex is dependent on several factors, such as the media's reducing potential and the presence of aggregates. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 33.33 mg/mL (77.72 mM), Sonication is recommended. |
| Keywords | Ubiquitin ligase | Ubiquitin conjugating enzyme | Ubiquitin activating enzyme | SJ-172550 | SJ172550 | SJ 172550 | MDMX | MDM-2/p53 | Inhibitor | inhibit | E3Enzyme | E3 ligating enzyme | E3 Enzyme | E2Enzyme | E2 Enzyme | E2 conjugating enzyme | E1Enzyme | E1/E2/E3 Enzyme | E1 Enzyme | E1 activating enzyme |
| Inhibitors Related | 10-Hydroxydecanoic Acid | Flubendazole | XI-006 | 2,5-Dihydroxybiphenyl | PYZD-4409 | Thiabendazole | NSC232003 | NAE-IN-M22 | Minocycline hydrochloride | Triglycidyl isocyanurate | C16 Ceramide | Indole-3-carbinol |
| Related Compound Libraries | Apoptosis Compound Library | Anti-Colorectal Cancer Compound Library | Anti-Pancreatic Cancer Compound Library | Bioactive Compound Library | Ubiquitination Compound Library | Anti-Cancer Metabolism Compound Library | Pyroptosis Compound Library | Inhibitor Library | PPI Inhibitor Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $2500.00/100mg |
VIP2Y
|
TargetMol Chemicals Inc.
|
2025-10-27 | |
| $0.00/10mg |
VIP2Y
|
ShenZhen H&D Pharmaceutical Technology Co., LTD
|
2024-07-11 | |
| $0.00/25kg |
VIP1Y
|
Qixia Lu Feng Industry and Trade Co Ltd
|
2025-03-07 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY